Next Article in Journal
Flavonoids from Machilus japonica Stems and Their Inhibitory Effects on LDL Oxidation
Next Article in Special Issue
Smoking and Rheumatoid Arthritis
Previous Article in Journal
Evaluation of the Antiradical Properties of Phenolic Acids
Previous Article in Special Issue
Environmental Factors, Toxicants and Systemic Lupus Erythematosus
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview

Targeting Dendritic Cell Function during Systemic Autoimmunity to Restore Tolerance

Millennium Institute of Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Portugal 49, Santiago 8330025, Chile
Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Marcoleta 350, Santiago 8330033, Chile
INSERM, UMR 1064, Nantes 44093, France
Author to whom correspondence should be addressed.
Present Address: Millennium Institute on Immunology and Immunotherapy Departamento de Gen
Int. J. Mol. Sci. 2014, 15(9), 16381-16417;
Received: 26 June 2014 / Revised: 29 August 2014 / Accepted: 5 September 2014 / Published: 16 September 2014
(This article belongs to the Special Issue Environmental Toxicants and Autoimmune Disease)
PDF [1152 KB, uploaded 16 September 2014]


Systemic autoimmune diseases can damage nearly every tissue or cell type of the body. Although a great deal of progress has been made in understanding the pathogenesis of autoimmune diseases, current therapies have not been improved, remain unspecific and are associated with significant side effects. Because dendritic cells (DCs) play a major role in promoting immune tolerance against self-antigens (self-Ags), current efforts are focusing at generating new therapies based on the transfer of tolerogenic DCs (tolDCs) during autoimmunity. However, the feasibility of this approach during systemic autoimmunity has yet to be evaluated. TolDCs may ameliorate autoimmunity mainly by restoring T cell tolerance and, thus, indirectly modulating autoantibody development. In vitro induction of tolDCs loaded with immunodominant self-Ags and subsequent cell transfer to patients would be a specific new therapy that will avoid systemic immunosuppression. Herein, we review recent approaches evaluating the potential of tolDCs for the treatment of systemic autoimmune disorders. View Full-Text
Keywords: autoimmunity; tolerance; therapy; dendritic cells autoimmunity; tolerance; therapy; dendritic cells

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Mackern-Oberti, J.P.; Vega, F.; Llanos, C.; Bueno, S.M.; Kalergis, A.M. Targeting Dendritic Cell Function during Systemic Autoimmunity to Restore Tolerance. Int. J. Mol. Sci. 2014, 15, 16381-16417.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top